Background to and management of treatment-related bone loss in prostate cancer

Drugs and Aging

Volumn 19, Issue 12, 2002, Pages 899-910

  Berruti, Alfredo ^a   Tucci, Marcello ^a   Terrone, Carlo ^a   Gorzegno, Gabriella ^a   Scarpa, Roberto M ^a   Angeli, Alberto ^a   Dogliotti, Luigi ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANDROGEN; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CORTICOTROPIN; ESTROGEN; ETIDRONIC ACID; GONADORELIN DERIVATIVE; IBANDRONIC ACID; LUTEINIZING HORMONE; PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN; RISEDRONIC ACID; SEX HORMONE BINDING GLOBULIN; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE METASTASIS; BONE MINERAL; CANCER HORMONE THERAPY; CLINICAL TRIAL; DIET SUPPLEMENTATION; FATIGUE; FRACTURE; HOT FLUSH; HUMAN; IMPOTENCE; LIFESTYLE; ORCHIECTOMY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANDROGEN ANTAGONISTS; BONE DISEASES, METABOLIC; CLINICAL TRIALS; DIPHOSPHONATES; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; OSTEOPOROSIS; PATIENT SELECTION; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0036941984     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219120-00002     Document Type: Review

References (73)

1. Crocetti E, Buiatti E, Amorosi A. Prostate cancer: population-based survival rates in central Italy. Tumori 1995; 81: 81-5
2. Dennis LK, Resnick MI. Analysis of recent trends in prostate cancer incidence and mortality. Prostate 2000; 42: 247-52
3. Small EJ. Prostate cancer: incidence, management and outcomes. Drugs Aging 1998; 13 (1): 71-81
4. Denis LJ. Staging and prognosis of prostate cancer. Eur Urol 1993; 24 Suppl. 2: 13-8
5. Van Cangh PJ, Gala JL, Tombal B. Immediate vs delayed androgen deprivation for prostate cancer. Prostate 2000; Suppl. 10: 19-25
6. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7
7. Meltzer D, Egleston B, Abballa I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 2001; 91: 126-8
8. Whitmore WF. Natural history and staging of prostate cancer. Urol Clin North Am 1984; 11: 205-20
9. Taplin ME, Shuk-Mei H. The endocrinology of prostate cancer. J Clin Endocrinol Metab 2001; 86: 3467-77
10. Matsushima H, Goto T, Hosaka Y, et al. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 1999; 85: 1822-7
11. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-8
12. Galbraith SM, Duchesne GM. Androgens and prostate cancer: biology, pathology and hormonal therapy. Eur J Cancer 1997; 33: 545-54
13. The Medical Research Council Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-46
14. Bolla M, Gonzales D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300
15. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
16. Wasson JH, Fowler FJ, Barry MJ. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J Urol 1998; 159: 1993-7
17. Stege R. Potential side effects of endocrine treatment of long duration in prostate cancer. Prostate 2000; Suppl. 10: 38-42
18. Seeman E. Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities. Am J Med 1993; 95 Suppl. 5A: 22-8
19. Selby PL, Davies M, Adams JE. Do men and women fracture bones at similar bone densities? Osteoporos Int 2000; 11: 153-7
20. Orwoll ES. Androgen: basic biology and clinical implication. Calcif Tissue Int 2001; 69: 185-8
21. Hughes CL, Wall LL, Creasman WT. Reproductive hormone levels in gynaecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol 1991; 40: 42-5
22. Stepan JJ, Lachman M, Zverina J, et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodelling. J Clin Endocrinol Metab 1989; 69: 523-7
23. Collinson MP, Tyrrel CJ, Hutton C. Osteoporosis occurring in two patients receiving LHRH analogues for carcinoma of the prostate. Calcif Tissue Int 1994; 54: 327-8
24. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44
25. Shaun A. McGrath G, Diamond T. Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol 1995; 154: 535-6
26. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999; 54: 607-11
27. Kiratli JB, Srinivas S, Perkash I, et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127-32
28. Stoch SA, Parker RA, Chen L. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86 (6): 2787-91
29. Eriksson S, Eriksson A, Stege R, et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogen. Calcif Tissue Int 1995; 57: 97-9
30. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6
31. Diamond T, Campbell J, Bryant C, et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83 (8): 1561-6
32. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-22
33. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in prostate cancer patients without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361-7
34. Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone naïve-men with prostate carcinoma. Cancer 2001; 91: 2238-45
35. Daniell HW, Tam EW. Testicular atrophy in therapeutic orchiectomy specimens from men with prostate carcinoma: association with prior prostate bed irradiation and older age. Cancer 1998; 83: 1174-9
36. Hatano T, Oishi Y, Furuta A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. Br J Urol 2000; 86: 449-52
37. Towsend MF, Sanders WH, Northway RO, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer 1997; 79: 545-50
38. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-8
39. Jacobsen SJ, Goldberg J, Miles TP, et al. Hip fracture incidence among the old and the very old: a population based study of 745,435 cases. Am J Public Health 1990; 80: 871-3
40. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength and adiposity. J Clin Endocrinol Metab 1998; 83 (6): 1886-92
41. Berruti A, Dogliotti L, Tucci M, et al. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 2001; 166 (6): 2023-31
42. Berruti A, Piovesan A, Torta M, et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 1996; 73: 1581-7
43. Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999; 45: 1240-7
44. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in bone metastatic prostate cancer patients with hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248-53
45. Higano CS, Stephens C, Nelson P, et al. Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS) [abstract]. Proc Am Soc Clin Oncol 1999; 18: 314a
46. Gluer CC. The use of bone densitometry in clinical practice. Bailliere's Clin Endocrinol Metab 2000; 14: 195-211
47. Stepan JJ. Prediction of bone loss in postmenopausal women. Osteoporos Int 2000; 11 Suppl. 6: 66-76
48. Bilezikian JP, Panel Members. Optimal calcium intake: statement of the consensus development panel on optimal calcium intake. JAMA 1994; 272: 1942-8
49. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years or older. N Engl J Med 1997; 337: 670-6
50. Kanis JA, McKloskey EV, O'Doherty D. Treatment of Paget's disease with the new bisphosphonates. In: Singer R, Wallach S, editors. Paget's disease of bone: clinical assessment present and future therapy. New York: Elsevier, 1991: 112
51. Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989; II: 1469-71
52. Ralston SH. Pathogenesis and management of cancer associated hypercalcemia. Cancer Surv 1994; 21: 179-96
53. Berenson JR, Linchtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia study group. N Engl J Med 1996; 334: 488-93
54. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic metastases: protocol 19. Aredia breast cancer study group. N Engl J Med 1996; 335: 1785-91
55. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International bone and cancer study group. J Clin Oncol 1998; 16 (12): 3890-9
56. Dearnaley DP, Sydes MR, on behalf of the MRC PR05 collaborators. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 trial [abstract]. Proc Am Soc Clin Oncol 2001; 693: 174a
57. Saad F, Gleason DM, Murray R, et al. A randomized, placebo controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68
58. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919-44
59. Degroen PC, Lubbe DF, Hisch LJ, et al. Esophagitis associated with the use of aledronate. N Engl J Med 1996; 335: 1016-21
60. Reid IR. Pharmacological management of osteoporosis in postmenopausal women. Drugs Aging 1999; 15 (5): 349-63
61. Orwoll E, Ettinger M, Weiss S, et al. Aledronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-10
62. Gonnelli S, Cepollaro C, Montagnani A, et al. Aledronate treatment in men with primary osteoporosis: a 3-year longitudinal study [abstract F398]. J Bone Miner Res 2000; 15 Suppl. 1: 228
63. Clarke NW, McClureJ, George NJ. The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. Scand J Urol Nephrol 1993; 27 (4): 475-83
64. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001; 92: 1444-50
65. Smith MR, McGovern FJ, Zietman AL. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-55
66. Cheer SM, Noble S. Zoledronic acid. Drugs 2001; 61(6): 799-805
67. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58 Suppl. 2A: 101-7
68. Scherr D, Pitts WR, Vaughan Jr DE. Diethylstibesterol revisited: androgen deprivation osteoporosis and prostate cancer. J Urol 2002; 167: 535-8
69. Cox RL, Crawford DE. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991-8
70. Calero JA, Diaz-Curiel M, de La Pedra C. Bicalutamide (Casodex) treatment does not produce bone effects in male Wistar rats [abstract F034]. J Bone Miner Res 1999; 14 Suppl. 1: 220
71. Abrahamsson PA. Treatment of locally advanced prostate cancer: a new role for antiandrogen monotherapy? Eur Urol 2001; 39 Suppl. 1: 22-8
72. Chodak G, Sharifi R, Kasimis B, et al. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46 (6): 849-55
73. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000; 164 (5): 1579-82